著者
中野 悦次 吉岡 俊昭 松田 稔 園田 孝夫 矢野 久雄 伊原 義博 黒田 秀也 岸本 知己 櫻井 勗 内田 欽也 児島 康行 中村 隆幸 清原 久和 佐川 史郎 関井 謙一郎 古武 敏彦 宇佐美 道之 三木 恒治 黒田 昌男 細木 茂 前田 修 友岡 義夫 吉村 一宏 水谷 修太郎 岩尾 典夫 三好 進 井上 彦八郎 本城 充 藤岡 秀樹 本多 正人 高羽 津 岡 聖次 松宮 清美 原 恒男 三宅 修 坂口 洋 竹山 政美 板谷 宏彬 宇都宮 正登 伊東 博 新 武三 永野 俊介 市川 靖二 野島 道生 長船 匡男 客野 宮治 山口 誓司 多田 安温
出版者
泌尿器科紀要刊行会
雑誌
泌尿器科紀要 (ISSN:00181994)
巻号頁・発行日
vol.36, no.5, pp.635-642, 1990-05

膀胱乳剤にフェルビナクのエチルエステルを封入させたLM-001静注剤を尿路結石による疼痛と膀胱・前立腺手術後の膀胱切迫感に対する有効性ならびに安全性について検討した.1)尿路結石による疼痛に対しては53例中49例に効果がみられた.有効例49例中41例までが本剤投与15分以内に効果が発現した.また26例において効果が24時間以上持続した.2)膀胱・前立腺手術後の膀胱切迫感に対しても29例中25例に効果がみられた.有効例25例中16例までが15分以内に効果発現した.また13例において効果が24時間以上持続した.3)副作用として血管痛,熱感,視力軽度低下,血圧の一時低下がみられたが,いずれもきわめて軽度で何ら処置することもなく短期間に消失した.また,3例に白血球増多,1例にA1-pの上昇がみられたが,その程度は軽度であり,すぐに正常化した.4)LM-001は尿路結石による疼痛の緩和と膀胱・前立腺手術後の膀胱切迫感に対し,速効性で高い有効率を示し,かつ作用時間が長いこと,また副作用がきわめて少ないことから優れた薬剤と評価し得たClinical effect of LM-001, a prostaglandin synthetic inhibitor developed from a drug delivery system, was evaluated in 54 patients with pain from urinary tract stones (stone pain) and 32 with vesical urgency after an operation on bladder or prostate. LM-001, felbinac ethyl incorporated in lipid microsphere, wes intravenously administered at the onset of stone pain or vesical urgency. Of 54 with stones and 32 with urgency, 53 and 29 were eligible for response, respectively. The symptoms improved or disappeared in some cases just after the administration and in the majority of patients within 15 minutes, in 49 of 53 patients with stone pain. Further, the effectiveness lasted over 24 hours in 26 of the 49 responding to this agent. On one hand, improvement or disappearance of vesical urgency was recognized in 25 of 29 patients, and the effectiveness was observed shortly after injection in 16 and lasted over 24 hours in 13 cases. Toxicities of this drug were investigated in 54 patients with stone pain and 32 with urinary urgency. Side effects consisted of pain at the injection site in 4, a slight fall of blood pressure in 1, slight visual disturbance in 1, body heat sensation in 1, leukocytosis in 3 and elevation of alkaline phosphatase in 1. These symptoms were transient and disappeared without use of any agent. LM-001 is concluded to be a useful drug for controlling stone pain and vesical urgency since an immediate effect, long durability and high response rates were obtained without severe side
著者
中野 悦次
出版者
泌尿器科紀要刊行会
雑誌
泌尿器科紀要 (ISSN:00181994)
巻号頁・発行日
vol.38, no.11, pp.1305-1309, 1992-11

腎摘除術時すでに転移巣をもつ9例を含む,15例にLAK細胞を週一度,IL-2毎日と併用で治療した。肺転移の10例のうち4例に部分反応(PR)がみられ,腫瘍の縮小がみられる。副作用として頭痛,悪寒,戦慄が全例にみられるが経口解熱剤でコントロールできた。IL-2の副作用として,発熱,浮腫,好酸菌増多があった。PR 4例中1例は脳転移で死亡したが,3例は生存中である。脳転移はNC・PDの例も含めて施行を合わせると脳転移が4例と多いFifteen patients with metastatic renal cell carcinoma (RCC) were treated by administration of autologous lymphokine-activated killer (LAK) cells given together with systemic administration of interleukin-2 (IL-2). Pulmonary metastases alone were found in 10 cases, pulmonary and mediastinal nodal metastases in 3, and pulmonary and bone metastases in 2. LAK cells, generated by incubation in 700 units/ml of IL-2 for 3-4 days, were intravenously administered once a week. In addition, beginning on the day of the first LAK cell infusion, 3.5 x 10(5) units of IL-2 were intravenously infused once or twice a day with occasional supplementation of 3.5 x 10(5) units of IL-2 on each day of LAK cell infusion. The total number of LAK cells and total amount of IL-2 administered per patient in this study ranged from 0.8 x 10(10) to 6.9 x 10(10) cells and from 10.2 x 10(6) to 74.9 x 10(6) units, respectively. As toxic effects caused by the infusion of LAK cells, headache, shaking chills, fever and leukocytosis were found in all cases. Side effects possibly induced by IL-2 infusion were tolerable fever, fluid retention (body weight gain of 2-3 kg) and eosinophilia. Out of 15 patients, a partial response was observed in 4 patients who had pulmonary metastases alone. One of the 4 patients with a partial response was clinically free of disease after undergoing a thoracotomy for resection of residual lesions, but a brain metastasis was detected 10 months after the thoracotomy. The remaining 3 patients are being closely followed up at present.(ABSTRACT TRUNCATED AT 250 WORDS)